Paper Details

  1. Home
  2. Paper Details

Cancer Risk in Patients with Multiple Sclerosis: Potential Impact of Disease-Modifying Drugs.

Author: LebrunChristine, RocherFanny

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

Some disease-modifying therapies (DMTs) for multiple sclerosis (MS) may increase cancer risk. Immunomodulatory (IM) drugs have not been linked to increased cancer risk, but some immunosuppressant (IS) drugs, such as mitoxantrone, azathioprine, and cyclophosphamide, have been associated with an increased risk. More research is needed to fully understand the potential risks of DMTs and to develop safer treatment options.
Paper Details　
Original Abstract of the Article :
In the 1990s, the first disease-modifying therapies (DMTs) for multiple sclerosis (MS) were injectable immunomodulatory (IM) drugs, including four different interferon-β preparations and glatiramer acetate. Since 2000, more than 15 immunosuppressant (IS) drugs have been used, with a more or less spe...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s40263-018-0564-y

データ提供：米国国立医学図書館（NLM）

Cancer Risk in Patients with Multiple Sclerosis: A Look at Disease-Modifying Drugs

This research explores the complex relationship between [multiple sclerosis (MS)] and [cancer], focusing on the potential impact of [disease-modifying drugs (DMTs)]. The study reviewed existing literature on [cancer risk] in [MS] patients treated with [DMTs], highlighting the importance of considering both the potential benefits and risks associated with these therapies. The authors emphasize the need for ongoing research to better understand the long-term effects of [DMTs] and develop more effective strategies for managing [cancer risk] in [MS] patients.

Navigating the Complexities of Cancer Risk and Disease-Modifying Therapies

The study's findings underscore the need for careful consideration of [cancer risk] in [MS] patients receiving [DMTs]. The authors recommend that clinicians engage in comprehensive risk-benefit assessments, factoring in individual patient characteristics and the specific [DMT] being considered. The findings highlight the critical importance of ongoing research to better understand the long-term implications of [DMTs] and develop more effective strategies for managing [cancer risk] in this vulnerable patient population.

Balancing Benefits and Risks in MS Treatment

The study's findings emphasize the need for a balanced approach to [MS] management, recognizing both the potential benefits and risks associated with [DMTs]. Clinicians should carefully consider the individual patient's needs and preferences, while also staying abreast of evolving research on the long-term effects of [DMTs]. The study underscores the importance of ongoing research and development in [MS] therapy, with the aim of improving patient outcomes while mitigating potential risks.

Dr. Camel's Conclusion

This research provides a comprehensive overview of the current knowledge regarding [cancer risk] in [MS] patients treated with [DMTs]. The study highlights the need for ongoing research to better understand the long-term effects of these therapies and develop effective strategies for managing potential risks while maximizing patient benefits. The authors emphasize the importance of a collaborative approach between clinicians and patients in navigating the complex terrain of [MS] management.

Date :
  1. Date Completed 2019-10-03
  2. Date Revised 2019-10-07
Further Info :

Pubmed ID

30143945

DOI: Digital Object Identifier

10.1007/s40263-018-0564-y

Related Literature

Article Analysis
・Effects of ocrelizumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.